ABUS vs WAT · P/E 5.4, rev $6.2M vs P/E 32, rev $1.65B
Arbutus Biopharma Corp (ABUS) versus Waters Corporation (WAT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Waters Corporation (WAT) is a diagnostics & research company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported WAT revenue for 2026-07-04 was $1.65B. Net income was -$136.0M. Revenue was up 29.8% from 2026-04-04 to 2026-07-04. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
Not investment advice. Open the ABUS and WAT stock pages for the full models.
Not investment advice.